Radiology and Medical Imaging Department, Fatima College of Health Sciences, Abu Dhabi 3798, United Arab Emirates.
National Cancer Institute, University of Gezira, Wad Madani 2667, Sudan.
Molecules. 2022 Aug 16;27(16):5231. doi: 10.3390/molecules27165231.
Advances in the field of molecular biology have had an impact on biomedical applications, which provide greater hope for both imaging and therapeutics. Work has been intensified on the development of radionuclides and their application in radiopharmaceuticals (RP) which will certainly influence and expand therapeutic approaches in the future treatment of patients. Alpha or beta particles and Auger electrons are used for therapy purposes, and each has advantages and disadvantages. The radionuclides labeled drug delivery system will deliver the particles to the specific targeting cell. Different radioligands can be chosen to uniquely target molecular receptors or intracellular components, making them suitable for personal patient-tailored therapy in modern cancer therapy management. Advances in nanotechnology have enabled nanoparticle drug delivery systems that can allow for specific multivalent attachment of targeted molecules of antibodies, peptides, or ligands to the surface of nanoparticles for therapy and imaging purposes. This review presents fundamental radionuclide properties with particular reference to tumor biology and receptor characteristic of radiopharmaceutical targeted therapy development.
分子生物学领域的进展对生物医学应用产生了影响，为成像和治疗提供了更大的希望。放射性核素的开发及其在放射性药物（RP）中的应用得到了加强，这将肯定会影响和扩大未来对患者的治疗方法。α或β粒子和俄歇电子用于治疗目的，每种粒子都有其优点和缺点。放射性核素标记的药物输送系统将粒子输送到特定的靶向细胞。可以选择不同的放射性配体来特异性靶向分子受体或细胞内成分，使它们适合于现代癌症治疗管理中针对个体患者的个性化治疗。纳米技术的进步使纳米颗粒药物输送系统能够实现针对抗体、肽或配体的靶向分子的特定多价附着，以实现治疗和成像目的。本文综述了基本的放射性核素特性，特别参考了肿瘤生物学和受体特性，以开发放射性药物靶向治疗。
